NCT04562883

Brief Summary

Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients. However, the approach is not widely used because of an efficiency gap compared to conventional ART. In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 5, 2020

Completed
19 days until next milestone

First Posted

Study publicly available on registry

September 24, 2020

Completed
7 days until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2020

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 24, 2021

Completed
Last Updated

July 25, 2023

Status Verified

July 1, 2023

Enrollment Period

2 months

First QC Date

September 5, 2020

Last Update Submit

July 23, 2023

Conditions

Keywords

CAPA-IVMSingle cultureGroup culture

Outcome Measures

Primary Outcomes (1)

  • Number of good quality embryos

    Number of good quality Day 3 embryos obtained

    At least 3 days after intra-cytoplasmic sperm injection

Secondary Outcomes (13)

  • Maturation rate

    Two days after oocytes pick-up

  • Fertilization rate

    16-18 hours after intra-cytoplasmic sperm injection

  • Cleavage rate

    At least 3 days after intra-cytoplasmic sperm injection

  • Expansion rate

    After at least 30 hours of maturation culture

  • The relative expression ratio ( R ) of human cumulus cell genes

    cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification

  • +8 more secondary outcomes

Study Arms (2)

Single Culture

EXPERIMENTAL

Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the "washing dish" containing "Maturation Medium" and wash them thoroughly. Then transfer COCs one by one to the "Culture dish" with "Maturation Medium".

Other: The way of Cumulus-oocyte complexes (COC) culture

Group Culture

EXPERIMENTAL

Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the "washing dish" containing "Maturation Medium (Group Culture)" by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the "IVM dish" with "Maturation Medium (Group Culture)".

Other: The way of Cumulus-oocyte complexes (COC) culture

Interventions

Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.

Group CultureSingle Culture

Eligibility Criteria

Age18 Years - 37 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the whole ovary and/or increased ovarian volume (\>10ml) (it is sufficient that 1 ovary fits these criteria)
  • No major uterine or ovarian abnormalities
  • Having at least 15 follicles on the OPU day
  • Patients consent to participate in the study

You may not qualify if:

  • High (\>grade 2) grade endometriosis
  • Cases with extremely poor sperm (serve OAT: density \<1 million, mobility \<10% and sperm from testicular surgery)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

My Duc Hospital

Ho Chi Minh City, Vietnam

Location

Related Publications (5)

  • Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9.

    PMID: 31399916BACKGROUND
  • Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4.

    PMID: 31902102BACKGROUND
  • Sanchez F, Romero S, De Vos M, Verheyen G, Smitz J. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum Reprod. 2015 Jun;30(6):1396-409. doi: 10.1093/humrep/dev083. Epub 2015 Apr 22.

    PMID: 25904637BACKGROUND
  • Saenz-de-Juano MD, Ivanova E, Billooye K, Herta AC, Smitz J, Kelsey G, Anckaert E. Genome-wide assessment of DNA methylation in mouse oocytes reveals effects associated with in vitro growth, superovulation, and sexual maturity. Clin Epigenetics. 2019 Dec 19;11(1):197. doi: 10.1186/s13148-019-0794-y.

    PMID: 31856890BACKGROUND
  • Sanchez F, Lolicato F, Romero S, De Vos M, Van Ranst H, Verheyen G, Anckaert E, Smitz JEJ. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod. 2017 Oct 1;32(10):2056-2068. doi: 10.1093/humrep/dex262.

MeSH Terms

Interventions

Culture Techniques

Intervention Hierarchy (Ancestors)

In Vitro TechniquesInvestigative Techniques

Study Officials

  • Tuong M Ho, MD, MCE

    Hope Research Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 5, 2020

First Posted

September 24, 2020

Study Start

October 1, 2020

Primary Completion

November 30, 2020

Study Completion

October 24, 2021

Last Updated

July 25, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations